Here we have used two different Hsp90 inhibitors, 17-AAG and ganetespib for in vivo studies, and demonstrated dramatic antitumor activity against both subcutaneous and metastatic tumor growth. This evidence concerns the gene HSP90AB1 and metastatic neoplasm.